Advertisement

Topics

AstraZeneca PLC Release: IMFINZI (Durvalumab) Granted Breakthrough Therapy Designation By U.S. FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

20:00 EDT 30 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: AstraZeneca PLC Release: IMFINZI (Durvalumab) Granted Breakthrough Therapy Designation By U.S. FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca PLC Release: IMFINZI (Durvalumab) Granted Breakthrough Therapy Designation By U.S. FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer"

Quick Search
Advertisement